Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083763 | 0.90 | EPHX2 (0.57) | LMNAEPHX2NR1H4MEN1KMT2A | |
| SCHEMBL8998273 | 0.79 | EPHX2 (0.66) | LMNAEPHX2NR1H4MEN1KMT2A | |
| SCHEMBL10561346 | 0.78 | EPHX2 (0.57) | LMNAEPHX2NR1H4MEN1KMT2A | |
| SCHEMBL9491290 | 0.77 | EPHX2 (0.55) | LMNAEPHX2NR1H4CA1CA2 | |
| SCHEMBL9493566 | 0.76 | EPHX2 (0.51) | LMNAEPHX2NR1H4MEN1KMT2A | |
| SCHEMBL19083765 | 0.76 | EPHX2 (0.53) | EPHX2NR1H4PPARG | |
| SCHEMBL9479093 | 0.76 | EPHX2 (0.53) | EPHX2NR1H4PPARG | |
| SCHEMBL9478351 | 0.75 | EPHX2 (0.52) | LMNAEPHX2NR1H4MEN1KMT2A | |
| SCHEMBL9479106 | 0.75 | EPHX2 (0.51) | LMNAEPHX2NR1H4MEN1KMT2A | |
| SCHEMBL9478572 | 0.75 | LMNA (0.42) | LMNAEPHX2NR1H4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | LMNA 462/4885EPHX2 952/4885NR1H4 529/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | LMNA 462/4885EPHX2 952/4885NR1H4 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.